MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
In this study, MGCD0103, a new anticancer drug under investigation, is given three times per week to elderly patients with previously untreated acute myelogenous leukemia/high risk myelodysplastic syndrome or adults with relapsed/refractory disease.
Myelogenous Leukemia, Acute|Myelodysplastic Syndromes
DRUG: MGCD0103
Safety and tolerability, 1 year (anticipated|Response rate, 1 year (anticipated)
Progression-free survival, 1 year (anticipated)|Duration of objective response, 1 year (anticipated)|Pharmacokinetics, 1 year (anticipated)|Pharmacodynamics, 1 year (anticipated)
In this study, MGCD0103, a new anticancer drug under investigation, is given three times per week to elderly patients with previously untreated acute myelogenous leukemia/high risk myelodysplastic syndrome or adults with relapsed/refractory disease.